| Axicabtagene Ciloleucel studied in …STUDIED_INderived39 of 39show fewer |
|---|
| → studied in | NCT05041309enrolling by invitation Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies · 39 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043323Phase 2 · recruiting A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma · 39 trials list this drug (21 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07479797Phase 3 · recruiting Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy · 39 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04608487Phase 1 · active not recruiting Axi-cel in CNS Lymphoma · 39 trials list this drug (21 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05075603Phase 1 · completed Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy · 39 trials list this drug (21 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07188558Phase 3 · recruiting A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy · 39 trials list this drug (21 active) | — | — | B-Cell Malignant Neoplasm,Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05077527Phase 1 · recruiting Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma · 39 trials list this drug (21 active) | — | — | Non-Hodgkin Lymphoma,AIDS-Related Non-Hodgkin Lymphoma,Transformed B-Cell Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04257578Phase 1/Phase 2 · active not recruiting Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma · 39 trials list this drug (21 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05776160available Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel · 39 trials list this drug (21 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07538635Phase 2 · recruiting CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. · 39 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05605899Phase 3 · active not recruiting Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma · 39 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04531046Phase 2 · active not recruiting Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation · 39 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02601313Phase 2 · completed Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) · 39 trials list this drug (21 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07042438Phase 2 · recruiting Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells · 39 trials list this drug (21 active) | — | — | Diffuse Large B-Cell Lymphoma,Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205838Phase 2 · terminated Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma · 39 trials list this drug (21 active) | — | — | Diffuse Large B-Cell Lymphoma,Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05459571Phase 2 · completed Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma · 39 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633615Phase 2 · recruiting Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · 39 trials list this drug (21 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03642626Phase 2 · active not recruiting MT2017-45: CAR-T Cell Therapy for Heme Malignancies · 39 trials list this drug (21 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04855253Phase 1/Phase 2 · suspended Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL · 39 trials list this drug (21 active) | — | — | Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07326371Phase 2 · not yet recruiting Glofitamab Combined With CAR-T Therapy in R/R DLBCL · 39 trials list this drug (21 active) | — | — | Interdigitating Dendritic Cell Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03105336Phase 2 · completed A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma · 39 trials list this drug (21 active) | — | — | Follicular Lymphoma,Indolent Non-Hodgkin Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03391466Phase 3 · completed Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma · 39 trials list this drug (21 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07254754Phase 2 · recruiting Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma · 39 trials list this drug (21 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04150913Phase 2 · completed A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity · 39 trials list this drug (21 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06550141Phase 2 · recruiting Emapalumab Prevention of CAR-T Cell Associated Toxicities · 39 trials list this drug (21 active) | — | — | Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05371093Phase 3 · active not recruiting Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma · 39 trials list this drug (21 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05794958Phase 1 · recruiting Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel · 39 trials list this drug (21 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06935136NA · not yet recruiting Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma · 39 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05108805Phase 4 · completed Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting · 39 trials list this drug (21 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06826118Phase 2 · recruiting Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma · 39 trials list this drug (21 active) | — | — | Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04432506Phase 2 · completed Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma · 39 trials list this drug (21 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03761056Phase 2 · completed Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma · 39 trials list this drug (21 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06609304Phase 4 · recruiting Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma · 39 trials list this drug (21 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03704298Phase 1 · terminated Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma · 39 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02348216Phase 1/Phase 2 · completed Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma · 39 trials list this drug (21 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02926833Phase 1/Phase 2 · completed Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · 39 trials list this drug (21 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04314843Phase 1 · terminated Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma · 39 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04002401Phase 2 · completed Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma · 39 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03153462approved for marketing Axicabtagene Ciloleucel Expanded Access Study · 39 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |